CCA
KZR

Catalyst Capital Advisors’s Kezar Life Sciences KZR Stock Holding History

Catalyst Capital Advisors’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-30
Closed -$7K – 435
2018
Q4 		$7K Hold
30
– – ﹤0.01% 327
2018
Q3 		$6K Hold
30
– – ﹤0.01% 385
2018
Q2 		$5K Buy
+30
New +$5.23K ﹤0.01% 439

Other funds holding KZR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CI
Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Catalyst Capital Advisors's KZR Position: Q1 2019 in Review

Catalyst Capital Advisors sold out of Kezar Life Sciences (KZR) in Q1 2019, closing a stake of 30 shares — an estimated $7K sold.

Catalyst Capital Advisors first reported a position in KZR in Q2 2018 and held it in 3 quarters. The position peaked at $7K in Q4 2018. 50 funds tracked by Wall St. Rank hold KZR as of Q1 2019.

  • Catalyst Capital Advisors reported no remaining Kezar Life Sciences position as of Q1 2019 after selling out during the quarter.
  • Catalyst Capital Advisors sold 30 Kezar Life Sciences shares in Q1 2019, an estimated $7K.
  • Catalyst Capital Advisors first reported a position in Kezar Life Sciences in Q2 2018 and held it in 3 quarters.
  • Catalyst Capital Advisors's Kezar Life Sciences position peaked at $7K in Q4 2018.
  • 50 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q1 2019.

Based on Catalyst Capital Advisors's 13F filing for Q1 2019, filed 8 May 2019.